Blog›Comparisons
Comparisons·15 min read·Published Jun 28, 2026·Updated Oct 20, 2026

Compounded Tirzepatide vs Zepbound 2026

Zepbound is FDA-approved; compounded tirzepatide is not. Who makes each, legal status, and Oct 2026 prices: $125–$432/mo vs $299–$449.

Nouri Editorial Team

Medically reviewed by Amber Patel, MD · Jun 28, 2026

Quick answer: Zepbound® is FDA-approved brand-name tirzepatide for weight management, made by Eli Lilly. Compounded tirzepatide is a non-FDA-approved version prepared patient-specifically by a licensed pharmacy. Our compounded tirzepatide guide covers its 2026 legal status. Same active ingredient — but not the same product: compounded versions are not FDA-approved, not studied in Zepbound's trials, and not therapeutically equivalent. The key difference most people weigh is cost. Zepbound costs $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg through LillyDirect; compounded tirzepatide runs $125 to $432 a month all-in at the starting dose across the 13 sellers in our compounded tirzepatide cost table. Both checked Oct 20, 2026.

As of Oct 20, 2026: prices re-checked on LillyDirect and in our compounded price table; FDA status re-checked in the Federal Register.

Key Takeaways
  • Same active ingredient (tirzepatide), but not the same product — compounded versions are not FDA-approved and were not studied in Zepbound's trials.
  • Cost (checked Oct 20, 2026): Zepbound $299–$449/mo through LillyDirect by dose (list price $499–$1,086.37 per fill); compounded tirzepatide $125–$432/mo all-in at the starting dose. Compounded is not FDA-approved.
  • The SURMOUNT-1 result — roughly 20.9% average body-weight reduction at the highest dose — is a finding from the brand-name Zepbound/Mounjaro trial. It does not apply to compounded tirzepatide, which has not been studied.
  • The FDA declared the tirzepatide shortage resolved (Oct 2, 2024, confirmed Dec 19, 2024), and the compounding grace periods ended in March 2025. Compounding should now be genuinely patient-specific and clinician-guided. The FDA's Apr 30, 2026 proposal to keep tirzepatide off the 503B bulks list was still not final as of Oct 20, 2026.

Compare tirzepatide prices →

At a glance: compounded tirzepatide vs Zepbound

Zepbound (brand)Compounded tirzepatide
FDA-approved?YesNo
Active ingredientTirzepatideTirzepatide (base API)
MakerEli LillyState-licensed compounding pharmacy
List price$499–$1,086.37 per fill (Lilly)None (not an approved product)
Self-pay / typical telehealth price$299 at 2.5 mg, $399 at 5 mg, $449 at 7.5–15 mg (LillyDirect vials or KwikPen, medication only)$125–$432/mo all-in at the starting dose (13 telehealth sellers)
Studied in clinical trialsYes (SURMOUNT program)No
Requires a prescription?YesYes
Dosing formatStandardized auto-injector pens / vials (2.5–15 mg)Vials, dose set by prescriber
Insurance eligible?Potentially (plan-dependent)Generally not covered
What's typically includedMedication onlyVaries; some programs include full clinical support
Boxed warningThyroid C-cell tumors (class warning)Same class warning applies

Sources: Eli Lilly prescribing information; FDA drug compounding guidance; SURMOUNT clinical-trial data (brand-name Zepbound/Mounjaro only). Prices checked Oct 20, 2026 and subject to change. Trial figures do not apply to compounded tirzepatide.

What is the difference between compounded tirzepatide and Zepbound?

The molecule is the same: tirzepatide, a dual GIP/GLP-1 receptor agonist. Everything else differs in ways that matter clinically and legally.

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Eli Lilly manufactures it under FDA-supervised processes — standardized formulation, validated potency, tamper-evident auto-injector pens and single-dose vials, and an ongoing post-market safety surveillance program. It went through extensive clinical trials before approval, including the SURMOUNT program.

Compounded tirzepatide is prepared patient-specifically by a state-licensed compounding pharmacy using tirzepatide as a raw active pharmaceutical ingredient (API). It is not FDA-approved: the FDA has not evaluated the compounded formulation's safety, efficacy, or quality. It was not studied in the SURMOUNT trials. There is no generic version of Zepbound — calling a compounded product "generic tirzepatide" is inaccurate and inconsistent with FDA guidance.

The distinction the FDA draws is important: compounding is intended for patients who have a specific clinical need that the approved product cannot meet — a particular dose, an allergy to an excipient, or a genuine access constraint. It is not intended as a routine lower-cost substitute for an FDA-approved product, though that is how it was widely used during the GLP-1 shortage era.

For a broader overview of how brand-name and compounded GLP-1s compare across both molecules, see our brand-name vs compounded GLP-1 overview.

Compounded tirzepatide vs Mounjaro

Mounjaro is Eli Lilly's other tirzepatide brand, FDA-approved for type 2 diabetes; Zepbound is the same molecule approved for chronic weight management (and for obstructive sleep apnea with obesity). Compounded tirzepatide is no closer to Mounjaro than to Zepbound: it is not FDA-approved, was not studied in either brand's trials, and is not a generic of either. On price, LillyDirect sells the Mounjaro single-dose pen for $499 a month at every dose (list price $1,112.16 per fill, checked Oct 20, 2026), more than Zepbound's $299–$449 self-pay ladder. The full breakdown is in Mounjaro cost without insurance.

How does the cost compare in 2026?

The cost gap between brand and compounded is real, though it has narrowed since the shortage era. Here is where prices stand as of Oct 20, 2026 — re-verify figures before acting on them, as pricing changes frequently across all parties.

Zepbound (brand-name tirzepatide) pricing

  • List price: $499–$1,086.37 per fill, depending on form and dose (Lilly's list price as of Jan 1, 2026), per Lilly's published pricing at pricinginfo.lilly.com/zepbound.
  • LillyDirect self-pay vials: Lilly sells Zepbound single-dose vials and KwikPens directly to self-paying patients at $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg if each refill comes within 45 days ($499–$699 otherwise; checked Oct 20, 2026), medication only. See LillyDirect for current pricing.
  • With insurance: Copays vary widely. Many plans exclude GLP-1s for weight management or require prior authorization. If you have coverage, Zepbound is the only tirzepatide option eligible for it.

Compounded tirzepatide via telehealth pricing

  • Market range: $125 to $432 a month all-in at the starting dose across the 13 telehealth sellers in our price table (checked Oct 20, 2026), counting every required fee. The lowest prices need a 6- or 12-month prepay; month to month, the range is $129 to $432. Some sellers charge the same at every dose; others charge more as the dose rises.
  • Not FDA-approved: whatever the price, compounded tirzepatide has not been reviewed by the FDA for safety, effectiveness or quality.

Lilly's self-pay tier has narrowed the gap considerably against program-level compounded pricing. The right comparison is like-for-like: brand vials from LillyDirect are medication only, with a separate cost for the prescribing visit. A program that includes clinical support, nutrition, and fitness alongside the medication at a higher per-month cost may represent a different value proposition depending on what you need. For a current look at how telehealth GLP-1 pricing compares across providers, see the GLP-1 telehealth pricing dataset (2026) and our complete GLP-1 cost guide for 2026. For tirzepatide-specific pricing details, see tirzepatide cost breakdown and Zepbound cost without insurance.

What does each option include?

Sticker-price comparisons can mislead when the included services differ. The table below maps what you typically get with each path.

What you getZepbound (LillyDirect self-pay)Compounded tirzepatide (telehealth, varies by provider)
Tirzepatide medicationYes — FDA-approved vialsYes — compounded vials (not FDA-approved)
Clinician consultationSeparate cost (your own provider or telehealth)Varies by provider
Nutrition planningNoVaries by provider
Fitness / movement planNoVaries by provider
Ongoing care supportNoVaries by provider
Dose flexibilityFixed commercial dose steps (2.5–15 mg)Prescriber-set; whether price changes by dose varies by provider
Satisfaction guaranteeNoVaries by provider
Insurance eligible?Yes (plan-dependent)Generally no; may qualify for FSA/HSA reimbursement (confirm with plan administrator)

Compounded tirzepatide from any provider is not FDA-approved and is not the same as, or therapeutically equivalent to, Zepbound®. FSA/HSA reimbursement eligibility for compounded GLP-1 medications varies — confirm with your plan administrator.

What does the tirzepatide research actually show?

All published clinical data on tirzepatide's effectiveness is research on brand-name tirzepatide — Zepbound® or Mounjaro® — not on compounded versions. Compounded tirzepatide has not been studied in controlled trials. With that framing in place, here is what the published research shows for the branded drug:

  • SURMOUNT-1 (Jastreboff et al., NEJM 2022): In a randomized controlled trial of brand-name tirzepatide in adults with obesity without type 2 diabetes, participants at the highest dose (15 mg) achieved an average body-weight reduction of approximately 20.9% over 72 weeks. Participants at lower doses averaged roughly 15–19.5% weight loss. These are population averages for the FDA-approved drug; individual results vary. Read the SURMOUNT-1 study →
  • SURMOUNT-5 (head-to-head vs. semaglutide, NEJM 2025): A direct comparison trial found brand-name tirzepatide was associated with greater mean weight reduction than semaglutide 2.4 mg (Wegovy®) — approximately 20.2% vs. 13.7% — over 72 weeks. Both figures are results for the FDA-approved branded medications. Read the SURMOUNT-5 study →

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides a clinician- and patient-facing overview of how prescription weight-management medications work and what to discuss with a provider. For how tirzepatide and semaglutide compare on this trial data, see our tirzepatide vs. semaglutide comparison.

None of the trial figures above apply to compounded tirzepatide. Compounded versions of this drug have not been studied, are not FDA-approved, and outcomes may differ.

Is compounded tirzepatide legal in 2026?

Compounding tirzepatide from a state-licensed 503A pharmacy with a valid individual prescription remains legal — but the regulatory environment is meaningfully different from 2022–2024, when the shortage opened a broad pathway for compounders.

What changed when the shortage ended

Between roughly 2022 and late 2024, the FDA listed tirzepatide on its drug shortage list. That listing allowed 503A and some 503B facilities to compound it more freely. In late 2024, the FDA declared the tirzepatide shortage resolved, and the broad shortage-based allowance closed. Since then:

  • 503A compounding pharmacies may still compound tirzepatide for individual patients with a valid prescription, when there is a genuine patient-specific need the commercial product cannot meet — a particular dose, an excipient allergy, or a documented access limitation.
  • 503B outsourcing facilities (which historically could compound in bulk without patient-specific prescriptions) lost the FDA's shortage grace period on Mar 19, 2025. On Apr 30, 2026, the FDA proposed not to put tirzepatide on the 503B bulks list (Federal Register, May 1, 2026), and on Jun 26, 2026 it extended the comment period to Jul 30, 2026 (Federal Register 2026-12937). As of Oct 20, 2026, no final notice has been published in the Federal Register: it is still a proposal.
  • The FDA sent warning letters to compounders and telehealth platforms that marketed compounded GLP-1s using equivalence language or without adequate disclosures about the non-FDA-approved status of the compound.

What this means for patients

Compounded tirzepatide from a named, licensed 503A pharmacy with a legitimate, patient-specific prescription is a legal pathway in 2026. But the FDA's posture has shifted: the agency expects compounding to serve genuine clinical needs, not to be a wholesale substitute for an approved product. The pharmacy should be identifiable and its license verifiable.

Because compounded tirzepatide is not FDA-reviewed, the FDA notes that its safety, purity, and potency have not been formally evaluated by the agency. Risks from unverified sources — counterfeits, incorrect concentration, contamination — are a documented concern. Compounding from a named, licensed 503A pharmacy with a real prescription substantially reduces these risks but does not eliminate them. The FDA's guidance on human drug compounding and its postmarket safety information on compounded GLP-1 drugs are the authoritative sources for current rules.

Both Zepbound and compounded tirzepatide carry the class-level boxed warning for potential thyroid C-cell tumors. Both are contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN 2, and neither should be used during pregnancy.

How does access work for each option?

The practical path to each product differs in ways worth understanding before you decide.

Getting Zepbound

Zepbound requires a prescription from a licensed provider. You can obtain one through your own primary care physician or endocrinologist, a telehealth platform that prescribes it, or via Eli Lilly's own LillyDirect service (which connects you with affiliated providers and its own pharmacy). If insured, prior authorization is required by most plans. The LillyDirect self-pay vial program bypasses the insurance step but still requires a telehealth consult and prescription; auto-injector pens are also available through retail pharmacies at list price.

Getting compounded tirzepatide through telehealth

Compounded tirzepatide is usually prescribed through an online telehealth provider. You complete a health questionnaire online; a U.S.-licensed clinician reviews it and determines whether treatment is clinically appropriate. Not everyone qualifies — medication should be prescribed only when indicated. If prescribed, the medication is prepared by a state-licensed 503A compounding pharmacy that should be named and verifiable, and is shipped to your home. What the price covers beyond the medication (nutrition or movement guidance, follow-up messaging), and whether it changes with dose, varies by provider — ask before you start.

For an overview of coverage options, see our guide on whether insurance covers Wegovy and Zepbound and using HSA/FSA funds for GLP-1s.

Related comparisons

Where compounded tirzepatide fits

If you and a licensed clinician determine a GLP-1 is appropriate for you, compounded tirzepatide is one option alongside Zepbound. Published cash prices, what each price includes, and the pharmacy behind the medication vary by provider, so compare them like-for-like before you choose. Nouri is an independent editorial resource that compares licensed providers and may earn a commission; it does not prescribe, dispense or sell medication.

Compounded tirzepatide contains the same active ingredient as Zepbound® (tirzepatide), but it is not FDA-approved, was not studied in Zepbound's trials, and is not the same as — or therapeutically equivalent to — Zepbound® or Mounjaro®. It is prescribed only when a licensed clinician determines it is clinically appropriate.

See what licensed providers charge →

Weighing the compounded option and unsure how to vet a program? Is compounded tirzepatide safe covers what not-FDA-approved actually means and how to verify the pharmacy and prescriber behind any offer.

No local clinic is required for either option: compounded tirzepatide near me explains how online prescribing and delivery replace the in-person visit in all 50 states.

Frequently asked questions

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No. Compounded tirzepatide shares the same active ingredient (tirzepatide) but is not FDA-approved, was not studied in the SURMOUNT trials, and is not therapeutically equivalent to Zepbound® or Mounjaro®. There is no generic version of either brand-name drug.

Is compounded tirzepatide cheaper than Zepbound?

Usually at the starting dose, but not always. Compounded tirzepatide runs $125 to $432 a month all-in at the starting dose across the 13 sellers in our price table, versus $299 to $449 for Zepbound through LillyDirect (both checked Oct 20, 2026), and 2 of those 13 sellers charge more than Zepbound's $299 starting price. Compare like for like: LillyDirect's price is medication only, while compounded prices include the provider's fees, and compounded tirzepatide is not FDA-approved.

Why is compounded tirzepatide less expensive than Zepbound?

Compounded tirzepatide is not manufactured, FDA-approved, or marketed as a brand-name drug — it is prepared patient-specifically by a licensed compounding pharmacy, without the research-and-development, clinical trial, and regulatory costs Eli Lilly incurred for Zepbound. The tradeoff: no FDA evaluation of the compounded product's safety, efficacy, or quality.

Is compounded tirzepatide legal in 2026?

Compounding from a state-licensed 503A pharmacy with a valid prescription remains legal. However, the FDA resolved the tirzepatide shortage in 2024–2025, ending the broad shortage-based compounding allowance. As of 2026, compounding is expected to be genuinely patient-specific and clinician-guided. The FDA also proposed on Apr 30, 2026 to keep tirzepatide off the 503B bulks list; the comment period closed Jul 30, 2026, and no final decision had been published as of Oct 20, 2026. Confirm current rules with a licensed clinician or pharmacy. Compounded tirzepatide is not FDA-approved.

Does insurance cover compounded tirzepatide?

Generally no — most commercial insurance plans do not cover compounded medications. Zepbound has potential for insurance coverage, though coverage for weight-management GLP-1s varies widely by plan and typically requires prior authorization. Compounded GLP-1 prescriptions may be eligible for FSA or HSA reimbursement under IRC §213(d) — typically with a receipt and, in some cases, a letter of medical necessity. Confirm eligibility with your plan administrator before assuming coverage.

Can I switch from Zepbound to compounded tirzepatide?

That is a clinical decision. A licensed provider should weigh your current dose, health history, insurance situation, and the reason for switching. Compounded and brand-name tirzepatide are not interchangeable products — any transition should be managed by a provider who can guide appropriate dosing and monitoring.

The bottom line

Zepbound is the FDA-approved, clinically studied product. Compounded tirzepatide is a non-FDA-approved option some people use under clinician guidance — typically for cost or access reasons — but it is not the same product, has not been studied in trials, and is not therapeutically equivalent. The regulatory environment tightened after the shortage resolved, and genuine clinical oversight is required.

If you and a licensed clinician decide compounded tirzepatide is the right path, compare providers on published price, what that price includes, and the named 503A pharmacy behind the medication. Compare licensed providers →

Sources & references

  1. Jastreboff AM, et al. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022. (Tier 1 — primary trial of brand-name tirzepatide)
  2. SURMOUNT-5: Tirzepatide vs Semaglutide head-to-head in obesity. NEJM 2025. (Tier 1 — primary head-to-head trial of brand-name tirzepatide)
  3. Wilding JPH, et al. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021. (Tier 1 — primary trial of brand-name semaglutide)
  4. FDA: Human Drug Compounding — regulatory guidance. (Tier 1)
  5. FDA: Postmarket Drug Safety Information — Compounded GLP-1 Drugs. (Tier 1)
  6. NIDDK: Prescription Medications to Treat Overweight and Obesity. (Tier 1 — NIH)
  7. LillyDirect: Zepbound self-pay vials and KwikPen (checked Oct 20, 2026). (Tier 3 — manufacturer pricing)
  8. Eli Lilly: Zepbound list price (as of Jan 1, 2026; checked Oct 20, 2026). (Tier 3 — manufacturer pricing)
  9. Federal Register 2026-08552: FDA proposes not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (May 1, 2026). (Tier 1)
  10. Federal Register 2026-12937: comment period extended to Jul 30, 2026 (Jun 26, 2026). (Tier 1; no final notice as of Oct 20, 2026)
  11. Nouri GLP-1 Telehealth Pricing Dataset 2026 — open pricing data across GLP-1 telehealth programs.

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · Last reviewed June 29, 2026. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

This article is general education, not medical advice — talk to a licensed clinician about what is right for you. Ozempic®, Wegovy®, and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Clinical-trial results described in this article are from studies of the FDA-approved branded medications (Zepbound®, Mounjaro®); compounded tirzepatide has not been studied in these trials, is not FDA-approved, and is not the same as — or therapeutically equivalent to — the brand-name drugs. GLP-1 medications carry a boxed warning for thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2; other risks include pancreatitis and gallbladder disease, and GLP-1 medications are not for use in pregnancy. Prices were checked Oct 20, 2026 and change frequently. FSA/HSA reimbursement eligibility for compounded medications varies — confirm with your plan administrator.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.

Before you choose

Compare licensed GLP-1 providers

Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.

← Back to all articles